Concerns grow over re-assessment of drug economic effectiveness

Published: 2009-01-20 06:58:00

Updated: 2009-01-20 06:58:00

The Health Insurance Review and Assessment Service plans to evaluate the economic effectiveness of 3,000-odd medicines covered by national health insurance, including leading antihypertensive agents, this year, triggering a concern from the pharmaceutical industry about price cuts.

The highlig...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK